Today, Cynata's CEO, Dr Kilian Kelly, presented at the MST Access Hidden Gems in Life Sciences Webinar. Watch the recording here:

MST Financial (“MST”) materials, or any portion thereof, may not be reproduced, sold or redistributed without the prior and written consent of MST. MST Access reports, updates, video interviews and other materials produced by MST Access have generally been engaged and paid by the subject company for ongoing research coverage. Please refer to full disclosures and disclaimers in the company-specific reports.

Listen to Professor John Rasko AO discussing the results of Cynata's Phase 1 clinical trial of CYP-001 in steroid-resistant acute GvHD, on the Australian Broadcasting Corporation Health Report with Dr Norman Swan and Tegan Taylor.

https://www.abc.net.au/listen/programs/healthreport/3d-printing-heart-transplant/103904548

Click here for a recording of the investor webinar on 9 May 2024, hosted by CEO & MD, Dr Kilian Kelly.

In case you missed it, Dr Kilian Kelly presented to brokers, fund managers, and high net-worth investors over lunch at the Establishment Ballroom, outlining Cynata's recent clinical trial milestones. Watch the presentation here:

Off the back of a string of positive announcements - DFU trial initial data, new CBO and first patient treated in aGVHD trial - Cynata CEO Dr Kilian Kelly sat down with Finance News Network to discuss The Company's milestones. Watch the interview below